利拉鲁肽治疗2型糖尿病患者动脉粥样硬化的作用分析  

Effects of Liraglutide in Treatment of Type 2 Diabetes Mellitus Patients with Atherosclerosis

作　　者：李燕妮[1] 仲健[1] 郭秋野[1] 白茜灵 LI Yan-ni ZHONG Jian GUO Qiu-ye BAI Qian-ling(Department of Endocrinology, Hanzhong Central Hospital, Hanzhong, Shaanxi 723000, Chin)

机构地区：[1]汉中市中心医院内分泌科,陕西汉中723000

出　　处：《解放军医药杂志》2017年第9期71-74,共4页Medical & Pharmaceutical Journal of Chinese People’s Liberation Army

基　　金：陕西省科技攻关基金资助项目(2011K32-06)

摘　　要：目的分析利拉鲁肽治疗2型糖尿病患者动脉粥样硬化作用的机制。方法回顾性分析2012年7月—2015年6月收治的118例2型糖尿病患者的临床资料,根据治疗方法分为观察组和对照组,每组59例。对照组采用二甲双胍和卡托普利治疗,观察组在对照组基础上加用利拉鲁肽注射液,持续治疗3个月。比较两组治疗效果、颈动脉内膜中层厚度(IMT)、血糖、血压、血脂等相关指标,记录不良反应发生率。结果观察组治疗总有效率高于对照组(P<0.05)。治疗后,两组空腹血糖、餐后2 h血糖、糖化血红蛋白、体重指数、收缩压、IMT、总胆固醇、甘油三酯和低密度脂蛋白胆固醇均明显低于治疗前(P<0.05),且观察组低于对照组(P<0.05);两组高密度脂蛋白胆固醇明显高于治疗前(P<0.05),观察组高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论利拉鲁肽能够通过降低血糖、调节血脂代谢、改善心肌功能和IMT来减轻2型糖尿病患者的动脉粥样硬化症状。Objective To analyze mechanism of Liraglutide in treatment of type 2 diabetes mellitus patients with atherosclerosis. Methods Clinical data of 118 patients with type 2 diabetes mellitus admitted during July 2012 and June 2015 was retrospectively analyzed, and the patients were divided into observation group and control group （n = 59 for each group） according to treatment methods. Control group was treated with Metformin and Captopril, while observation group was added with Liraglutide injection on the basis of treatment for control group, and continuous treatment was 3 months. Related indexes such as therapeutic effect, carotid intima media thickness （IMT）, blood glucose, blood pres- sure and blood lipids were compared, and incidence rates of adverse reactions were recorded in two groups. Results The total effective rate in observation group was significantly higher than that in control group （ P 〈 0. 05 ）. After treatment, fasting blood glucose, 2 h postprandial blood glucose, glycosylated hemoglobin, body mass index, systolic pressure, IMT, total cholesterol, triglyeeride and low density lipoprotein cholesterol levels were significantly lower than those before treatment in two groups （P 〈 0.05 ） , and the levels in observation group were significantly lower than those in control group （P 〈 0. 05 ） ; high-density lipoprotein cholesterol levels were significantly higher than those before treatment in two groups （P 〈 0. 05） , and the level in observation group was significantly higher than that in control group （ P 〈 0. 05 ）. There was no significant difference in incidence rate of adverse reactions between the two groups （P 〉 0. 05）. Conclu- sion Liraglutide can decrease coronary atherosclerosis symptoms by reducing blood sugar level, regulating blood lipid metabolism, improving myocardial function and IMT of type 2 diabetes mellitus patients with coronary atherosclerosis.

关 键 词：利拉鲁肽 糖尿病 2型 动脉粥样硬化 治疗效果 

分 类 号：R587.1[医药卫生—内分泌] R543.5[医药卫生—内科学]